

**Medicaid Preferred Drug List (PDL) Program:
Pharmacy and Therapeutics Committee Meeting
Wednesday, April 21, 2004
1:00 p.m. DMAS Board Room
AGENDA**

- **Welcome and Introductions** Patrick W. Finnerty, Director
- **Comments from the Chairperson** Randy Axelrod, M.D., Chairman
- **Acceptance of Minutes** P&T Committee Members
From February 9, 2004 P&T Meeting
- **Clarification of Cox II Criteria from February 9th Meeting** P&T Committee Members
- **Discussion of Combination Drug Review and Annual Drug Class Review** P&T Committee Members
- **Confidential Meeting** Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information
- **Drug Class and Criteria Discussions for July 2004:** P&T Committee Members
 - Carbonic Anhydrase Inhibitors - Ophth
 - Alpha 2 Adrenergics - Ophth
 - Beta-blockers – Ophth
 - Prostaglandin Inhibitors – Ophth
 - Narcotics: Long Acting
 - Antihyperkinesis/CNS Stimulants (Meds for ADD/ADHD)
 - Macrolides – Adult/Pediatric (Antibiotics)
 - Quinolones- Systemic (2nd & 3rd Generation Antibiotics)
 - Cephalosporins (2nd & 3rd Generation Antibiotics)
- **Open Issues** Randy Axelrod, M.D., Chairman
- **Next Meeting – Tuesday, May 18, 2004** Randy Axelrod, M.D., Chairman